Onglyza (saxagliptin) comarketed by Bristol-Myers Squibb and AstraZeneca, is FDA-approved to improve glycemic control for the treatment of type 2 diabetes.
Trang Ho
Advertisement
Articles by Trang Ho
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Key Pharmacotherapy Advances in Type 1 and Type 2 Diabetes
2
CagriSema Outperforms Semaglutide in Lowering HbA1C, Reducing Weight Across REIMAGINE Trials
3
McKesson ideaShare 2026: What Sets Health Mart's Pharmacy of the Year Finalists Apart
4
ADA 2026: Lipid Management and Cardiovascular Prevention Updates for People With Diabetes
5